242 related articles for article (PubMed ID: 28233730)
1. Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy.
Lázár-Molnár E; Scandiuzzi L; Basu I; Quinn T; Sylvestre E; Palmieri E; Ramagopal UA; Nathenson SG; Guha C; Almo SC
EBioMedicine; 2017 Mar; 17():30-44. PubMed ID: 28233730
[TBL] [Abstract][Full Text] [Related]
2. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.
Maute RL; Gordon SR; Mayer AT; McCracken MN; Natarajan A; Ring NG; Kimura R; Tsai JM; Manglik A; Kruse AC; Gambhir SS; Weissman IL; Ring AM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6506-14. PubMed ID: 26604307
[TBL] [Abstract][Full Text] [Related]
3. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.
Pen JJ; Keersmaecker BD; Heirman C; Corthals J; Liechtenstein T; Escors D; Thielemans K; Breckpot K
Gene Ther; 2014 Mar; 21(3):262-71. PubMed ID: 24401835
[TBL] [Abstract][Full Text] [Related]
4. DCs sensitized with mPD-L1-Ig fusion protein improve the effect of heart transplantation in mice by promoting the generation of T-reg cells.
Liu C; Chen H; Jia J; Hong T; Wang C
Cell Immunol; 2014 Jul; 290(1):169-77. PubMed ID: 24997656
[TBL] [Abstract][Full Text] [Related]
5. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
6. The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD).
Du J; Qin Y; Wu Y; Zhao W; Zhai W; Qi Y; Wang C; Gao Y
Cell Commun Signal; 2018 Jun; 16(1):25. PubMed ID: 29879980
[TBL] [Abstract][Full Text] [Related]
7. High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.
Liang Z; Li Y; Tian Y; Zhang H; Cai W; Chen A; Chen L; Bao Y; Xiang B; Kan H; Li Y
Cancer Lett; 2019 Apr; 447():164-173. PubMed ID: 30677447
[TBL] [Abstract][Full Text] [Related]
8. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
[TBL] [Abstract][Full Text] [Related]
9. Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity.
Shrestha R; Garrett SC; Almo SC; Fiser A
Structure; 2019 May; 27(5):829-836.e3. PubMed ID: 30930066
[TBL] [Abstract][Full Text] [Related]
10. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
[TBL] [Abstract][Full Text] [Related]
11. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Reinhardt K; Kermer V; Kontermann RE; Müller D
Cancer Immunol Immunother; 2013 Aug; 62(8):1369-80. PubMed ID: 23715927
[TBL] [Abstract][Full Text] [Related]
12. High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2.
Li Y; Liang Z; Tian Y; Cai W; Weng Z; Chen L; Zhang H; Bao Y; Zheng H; Zeng S; Bei C; Li Y
Cancer Sci; 2018 Aug; 109(8):2435-2445. PubMed ID: 29890018
[TBL] [Abstract][Full Text] [Related]
13. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
Woods DM; Sodré AL; Villagra A; Sarnaik A; Sotomayor EM; Weber J
Cancer Immunol Res; 2015 Dec; 3(12):1375-85. PubMed ID: 26297712
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human
Burova E; Hermann A; Waite J; Potocky T; Lai V; Hong S; Liu M; Allbritton O; Woodruff A; Wu Q; D'Orvilliers A; Garnova E; Rafique A; Poueymirou W; Martin J; Huang T; Skokos D; Kantrowitz J; Popke J; Mohrs M; MacDonald D; Ioffe E; Olson W; Lowy I; Murphy A; Thurston G
Mol Cancer Ther; 2017 May; 16(5):861-870. PubMed ID: 28265006
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of bovine programmed death-ligand 2.
Nishimori A; Konnai S; Ikebuchi R; Okagawa T; Nakajima C; Suzuki Y; Mingala CN; Murata S; Ohashi K
Microbiol Immunol; 2014 Jul; 58(7):388-97. PubMed ID: 24845976
[TBL] [Abstract][Full Text] [Related]
16. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
[TBL] [Abstract][Full Text] [Related]
17. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
20. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.
Deng R; Cassady K; Li X; Yao S; Zhang M; Racine J; Lin J; Chen L; Zeng D
J Immunol; 2015 Jan; 194(2):560-74. PubMed ID: 25488990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
